









Markets
/
Stocks
/
nasdaq-bdx
/

Becton Dickinson and Co

BDX

189.089USD

+0.059+0.03%

Market hours （ET）Quotes delayed by 15 min

54.20BMarket Cap

34.19P/E TTM



Becton Dickinson and Co

189.089

+0.059+0.03%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Becton Dickinson and Co

Currency: USD Updated: 2025-10-21

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Becton Dickinson and Co's Score

Industry at a Glance

Industry Ranking

10 / 204

Overall Ranking

47 / 4687

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 14 analysts

Buy

Current Rating

217.450

Target Price

+13.85%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Becton Dickinson and Co Highlights

StrengthsRisks

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 64.52%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 64.52%.

Undervalued

The company’s latest PE is 34.39, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 264.75M shares, decreasing 4.50% quarter-over-quarter.

Held by Al Gore

Star Investor Al Gore holds 2.76M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-21

The company's current financial score is 8.69, which is higher than the Healthcare Equipment & Supplies industry's average of 7.47. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 5.51B, representing a year-over-year increase of 10.40%, while its net profit experienced a year-over-year increase of 17.86%.

Score

Industry at a Glance

Previous score

8.69

Change



Financials

6.10

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.64

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.69

Key Metrics

Free cash flow

No Data

Becton Dickinson and Co's Company Valuation

Currency: USD Updated: 2025-10-21

The company’s current valuation score is 7.31, which is higher than the Healthcare Equipment & Supplies industry's average of 7.16. Its current P/E ratio is 34.39, which is 70.24% below the recent high of 58.55 and 8.88% above the recent low of 31.34.

Score

Industry at a Glance

Previous score

7.31

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 10/204

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-21

The company’s current earnings forecast score is 7.14, which is lower than the Healthcare Equipment & Supplies industry's average of 7.72. The average price target for Becton Dickinson and Co is 205.50, with a high of 281.50 and a low of 183.00.

Score

Industry at a Glance

Previous score

7.14

Change

Support & Resistance

No Data

Analyst Rating

Based on 14 analysts

Buy

Current Rating

217.450

Target Price

+13.85%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

116

Total

Median

Average

Company name

Ratings

Analysts

Becton Dickinson and Co

BDX

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-21

The company’s current price momentum score is 8.72, which is higher than the Healthcare Equipment & Supplies industry's average of 7.21. Sideways: Currently, the stock price is trading between the resistance level at 196.87 and the support level at 179.65, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.92

Change

-0.2

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.047

Buy

RSI(14)

50.618

Neutral

STOCH(KDJ)(9,3,3)

63.148

Buy

ATR(14)

4.081

High Vlolatility

CCI(14)

3.817

Neutral

Williams %R

38.368

Buy

TRIX(12,20)

-0.002

Sell

StochRSI(14)

65.158

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

188.234

Buy

MA10

188.576

Buy

MA20

188.442

Buy

MA50

190.498

Sell

MA100

183.361

Buy

MA200

198.977

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-21

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.37. The latest institutional shareholding proportion is 92.37%, representing a quarter-over-quarter increase of 0.01%. The largest institutional shareholder is The Vanguard, holding a total of 32.17M shares, representing 11.22% of shares outstanding, with 21.08% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

32.17M

+15.41%

T. Rowe Price Investment Management, Inc.

16.18M

+28.65%

BlackRock Institutional Trust Company, N.A.

15.15M

+2.44%

State Street Investment Management (US)

13.41M

-4.14%

First Eagle Investment Management, L.L.C.

Star Investors

8.79M

+59.18%

T. Rowe Price Associates, Inc.

Star Investors

8.47M

-22.27%

MFS Investment Management

7.69M

+25.78%

Geode Capital Management, L.L.C.

6.72M

+3.77%

ClearBridge Investments, LLC

3.80M

+9.24%

Norges Bank Investment Management (NBIM)

3.79M

+17.00%

Risk Assessment

Currency: USD Updated: 2025-10-21

The company’s current risk assessment score is 8.93, which is higher than the Healthcare Equipment & Supplies industry's average of 4.64. The company's beta value is 0.26. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.